Search - tctmd.com

Displaying 21 - 40 of 55

Sort: Relevancy | Date

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

News Conference News ACC 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

May 18, 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

News Conference News ACC 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Michael O'Riordan

May 16, 2021

Ultrasound Renal Denervation for Hypertension Resistant to a Triple Medication Pill: The Randomized Sham Controlled RADIANCE-HTN TRIO Trial

Presentation ACC 2021

Ultrasound Renal Denervation for Hypertension Resistant to a Triple Medication Pill: The Randomized Sham Controlled RADIANCE-HTN TRIO Trial

Presenter: Ajay J. Kirtane

May 16, 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

News Conference News ACC 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

Yael L. Maxwell

May 15, 2021

Wide Variation in TAVI Readmission Rates Among US Hospitals

News Conference News ACC 2021

Wide Variation in TAVI Readmission Rates Among US Hospitals

May 07, 2021

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Renal Denervation Lowers BP in Pivotal SPYRAL HTN-OFF MED Trial

News Conference News ACC 2020

Renal Denervation Lowers BP in Pivotal SPYRAL HTN-OFF MED Trial

March 30, 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

News Conference News ACC 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

Michael O'Riordan

March 28, 2020

Renal Denervation May Lower Treatment Burden, as Well as Blood Pressure: RADIANCE-HTN SOLO

News Conference News ACC 2019

Renal Denervation May Lower Treatment Burden, as Well as Blood Pressure: RADIANCE-HTN SOLO

Michael O'Riordan

April 01, 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

March 26, 2019

Chemical Renal Denervation with Alcohol: The Post-Market Study Data and The Target BP Program

Presentation ACC 2019

Chemical Renal Denervation with Alcohol: The Post-Market Study Data and The Target BP Program

Presenter: Horst Sievert

March 18, 2019

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

News Conference News ACC 2018

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

March 19, 2018

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

News Conference News ACC 2018

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

March 14, 2018

Thin Struts and ‘Pro-Healing’ Layer: Combo Stent Sees Success at 1 Year

News Conference News ACC 2018

Thin Struts and ‘Pro-Healing’ Layer: COMBO Stent Sees Success at 1 Year

Yael L. Maxwell

March 11, 2018

News Conference News ACC 2016

Hints of What’s to Come in New Coronary Revascularization AUC

April 12, 2016

News Conference News ACC 2016

Cardioband Transcatheter Mitral Annulus Repair Appears Safe, Effective in Functional MR

April 07, 2016

News Conference News ACC 2016

Vagus Nerve Stimulation Fails to Improve Clinical Outcomes in Chronic Heart Failure

April 05, 2016

News Conference News ACC 2015

Study EMBRACEs Novel Drug, But Fails to Reduce Infarct Size in Anterior STEMI

Yael L. Maxwell

March 15, 2015

News Conference News ACC 2015

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

March 15, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.